rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ELTX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Elicio Therapeutics: Q3 Earnings Snapshot
      Nov 5Yahoo FinanceELTX
      Elicio Therapeutics to Host Virtual KOL Event on November 11, 2026: ELI-002 7P for Metastatic and Neoadjuvant PDAC
      Nov 4Yahoo FinanceELTX
      Elicio to present KRAS vaccine data at cancer conference
      Oct 29Investing.comELTX
      Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting

      Keynote/plenary session and late-breaking poster presentation highlight additional data from Phase 2 AMPLIFY-7P trial of camupepimut (ELI-002 7P) in KRAS-mutated pancreatic cancerAdditional preclinical poster presentation showcases an expanded application of the AMP-platform in an antigen-agnostic intratumoral treatment approach BOSTON, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-ge

      Oct 29Yahoo FinanceELTX
      Elicio’s pancreatic cancer vaccine misses primary endpoint
      Oct 23Investing.comELTX
      Elicio to present new pancreatic cancer trial data at ESMO
      Sep 24Investing.comELTX
      Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026

      New pre-specified analyses from the randomized Phase 2 study will further characterize the clinical potential of ELI-002 7P (camupepimut) in adjuvant pancreatic cancerFindings are expected to inform a refined Phase 3 development strategy BOSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that new pre-specified ana

      Sep 24Yahoo FinanceELTX
      B. Riley Adjusts Price Target on Elicio Therapeutics to $8 From $27, Keeps Buy Rating

      Elicio Therapeutics (ELTX) has an average rating of buy and mean price target of $19.13, according t

      Sep 24Yahoo FinanceELTX
      Elicio Therapeutics Sets Key 2026 Shareholder Proposal Deadlines

      Detailed price information for Elicio Therapeutics Inc (ELTX-Q) from The Globe and Mail including charting and trades.

      Sep 15The Globe and MailELTX
      Elicio Therapeutics at H.C. Wainwright: pivot to metastatic cancer
      Sep 14Investing.comELTX
      Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference

      BOSTON, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that Robert Connelly, Chief Executive Officer and Pete DeMuth, PhD, Chief Scientific Officer, will participate in a fireside chat at the upcoming H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, in New York, New York. H.C

      Aug 31Yahoo FinanceELTX
      Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

      BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that management will participate in one-on-one meetings at the upcoming Wells Fargo 21st Annual Healthcare Conference, taking place September 8-10, 2026, in Boston, MA. Wells Fargo 21st Annual Healthcare ConferenceFormat: One-on-one MeetingsDate: Thursday, September

      Aug 24Yahoo FinanceELTX

      This is the newest page. Registered accounts read further back.